| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 32,562,612 | 34,259,637 | ||
| Accounts receivable | - | 134,599 | ||
| Prepaid expenses and other current assets | 359,909 | 729,598 | ||
| Total current assets | 32,922,521 | 35,123,834 | ||
| Goodwill | 9,600,240 | 9,600,240 | ||
| In-process research and development | 4,800,000 | 4,800,000 | ||
| Property and equipment, net | 12,933 | 15,361 | ||
| Right-of-use asset | 223,698 | 265,444 | ||
| Other non-current assets | 18,996 | 18,996 | ||
| Total assets | 47,578,388 | 49,823,875 | ||
| Accounts payable | 745,958 | 569,445 | ||
| Accrued liabilities and other current liabilities | 1,888,833 | 1,893,889 | ||
| Deferred revenue | 521,899 | - | ||
| Operating lease liability | 180,751 | 184,842 | ||
| Total current liabilities | 3,337,441 | 2,648,176 | ||
| Deferred tax liability | 201,792 | 201,792 | ||
| Other non-current liabilities | 74,399 | 117,038 | ||
| Total liabilities | 3,613,632 | 2,967,006 | ||
| Common stock, 0.001 par value 100,000,000 shares authorized at september 30, 2025 and december 31, 2024 49,046,246 and 49,046,246 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 49,046 | 49,046 | ||
| Additional paid-in capital | 479,989,433 | 479,831,741 | ||
| Accumulated other comprehensive loss | -126,803 | -127,371 | ||
| Accumulated deficit | -435,946,920 | -432,896,547 | ||
| Total stockholders equity | 43,964,756 | 46,856,869 | ||
| Total liabilities and stockholders' equity | 47,578,388 | 49,823,875 | ||
MEDICINOVA INC (MNOV)
MEDICINOVA INC (MNOV)